RGNX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 6.83% compared to Regenxbio's net margin of -49.65%. Regenxbio's return on equity of -50.09% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Regenxbio has a consensus price target of $31.75, signalling upside risk potential of 265.78%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Regenxbio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Regenxbio is more attractive than NovaBay Pharmaceuticals.

Regenxbio has a beta of 1.061, which suggesting that the stock is 6.051% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Regenxbio's net income of $6.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Regenxbio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 2.82x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 6.83% compared to Regenxbio's net margin of 21.63%. Regenxbio's return on equity of -50.09% beat Pfizer's return on equity of 8.72%.

Regenxbio has a consensus price target of $31.75, signalling upside risk potential of 265.78%. On the other hand Pfizer has an analysts' consensus of $29.14 which suggests that it could grow by 13.62%. Given that Regenxbio has higher upside potential than Pfizer, analysts believe Regenxbio is more attractive than Pfizer.

Regenxbio has a beta of 1.061, which suggesting that the stock is 6.051% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.63% to investors and pays a quarterly dividend of $0.43 per share. Regenxbio pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than Pfizer quarterly revenues of $13.7B. Regenxbio's net income of $6.1M is lower than Pfizer's net income of $3B. Notably, Regenxbio's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 2.82x versus 2.34x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of 6.83% compared to Regenxbio's net margin of --. Regenxbio's return on equity of -50.09% beat Rocket Pharmaceuticals's return on equity of --.

Regenxbio has a consensus price target of $31.75, signalling upside risk potential of 265.78%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $9.03 which suggests that it could grow by 263.74%. Given that Regenxbio has higher upside potential than Rocket Pharmaceuticals, analysts believe Regenxbio is more attractive than Rocket Pharmaceuticals.

Regenxbio has a beta of 1.061, which suggesting that the stock is 6.051% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.232%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Regenxbio's net income of $6.1M is higher than Rocket Pharmaceuticals's net income of -$61.3M. Notably, Regenxbio's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 2.82x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 6.83% compared to Regenxbio's net margin of -60.08%. Regenxbio's return on equity of -50.09% beat Sarepta Therapeutics's return on equity of -20.94%.

Regenxbio has a consensus price target of $31.75, signalling upside risk potential of 265.78%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 163.95%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.061, which suggesting that the stock is 6.051% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Regenxbio's net income of $6.1M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 2.82x versus 0.90x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.